CTMX

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is an oncology-focused biopharmaceutical company founded in 2008 and headquartered in South San Francisco, California. The company went public in October 2015 and has developed a proprietary technology platform called Probody therapeutics for creating conditionally activated cancer treatments. CytomX operates primarily as a research and development organization, advancing both internal drug candidates and partnered programs with major pharmaceutical companies including Bristol-Myers Squibb, Amgen, Astellas, and others.